Place of phosphatidylcholine in the treatment of inflammatory bowel disease

A.E. Dorofeev, N.N. Rudenko, N.I. Shvets, A.A. Dorofeeva

Abstract


In the pathogenesis of most diseases of the intestine, inflammation is important, and, often, critical. Its pathogenetic role in the inflammatory bowel disease was studied broadly and comprehensively. In recent years, research has begun on its contribution to intestinal damage in functional pathology — irritable bowel syndrome. The participation of inflammation in the development of erosive and ulcerative lesions of the lower gastrointestinal tract on the background of non-steroidal anti-inflammatory drugs (NSAID-enterocolopathy) seems paradoxical. The role of phospholipids in the construction of cell membranes is well known. One of the main membrane phospholipids of most living organisms (with the exception of microbes) is phosphatidylcholine (PC). In membranes of the intestinal epithelium, the content of PC increases from 10 to 50 % in the direction from the apical surface to the basal one, and the maximum amount of PC is located on the outside of the cell membranes. Phosphatidylcholine showed its high efficacy and safety in the treatment of inflammatory bowel diseases, such as non-specific ulcerative colitis. People taking NSAIDs have demonstrated the protective role of PC in preventing damage to the upper and lower gastrointestinal tract. Given the common pathogenetic mechanisms between these diseases and irritable bowel syndrome, the use of PC in patients with irritable bowel syndrome seems promising, especially in its post-infection variant.

Keywords


intestinal diseases; phosphatidylcholine

References


Dorofeyev AE, Rudenko NN. Nonulcerative colitis. Current state of problem. Suchasna gastroenterologija. 2015;6(86):53-8. (in Russian).

Dorofeyev AE, Rudenko NN. NSAIDs-enteropathy: mechanisms of injury and ways to prevent. Novosti Meditsiny i Farmatsii. 2015;4(533):6-8. (in Russian).

Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G922-9. PMID: 11292601.

Braun A, Treede I, Gotthardt D, et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis. 2009 Nov;15(11):1705-20. doi: 10.1002/ibd.20993.

Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015 Aug;50(8):942-51. doi: 10.3109/00365521.2015.1014407.

Chang J, Leong RW, Wasinger V, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology. 2017 Sep;153(3):723-731.e1. doi: 10.1053/j.gastro.2017.05.056.

Dorofeyev AE, Vasilenko IV, Rassokhina OA, Kondratiuk RB. Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract. 2013;2013:431231. doi: 10.1155/2013/431231.

Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W. Phosphatidylcholine as a constituent in the colonic mucosal barrier--physiological and clinical relevance. Biochim Biophys Acta. 2010 Sep;1801(9):983-93. doi: 10.1016/j.bbalip.2010.05.014.

Farré R, Vicario M. Abnormal Barrier Function in Gastrointestinal Disorders. Handb Exp Pharmacol. 2017;239:193-217. doi: 10.1007/164_2016_107.

Hirase T, Kawashima S, Wong EY, et al. Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. J Biol Chem. 2001 Mar 30;276(13):10423-31. doi: 10.1074/jbc.M007136200.

Johansson ME. Mucus layers in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Nov;20(11):2124-31. doi: 10.1097/MIB.0000000000000117.

Karner M, Kocjan A, Stein J, et al. First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol. 2014 Jul;109(7):1041-51.doi: 10.1038/ajg.2014.104.

Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010 Mar;55(3):716-23. doi: 10.1007/s10620-009-0765-9.

Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031.

Lanas A, Sopeña F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am. 2009 Jun;38(2):333-52. doi: 10.1016/j.gtc.2009.03.007.

Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol. 2006 Nov;58(11):1421-8. doi: 10.1211/jpp.58.10.0001.

Lichtenberger LM, Zhou Y, Jayaraman V, et al. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine. Biochim Biophys Acta. 2012 Jul;1821(7):994-1002. doi: 10.1016/j.bbalip.2012.04.002.

Lim YJ, Dial EJ, Lichtenberger LM. Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety. Gut Liver. 2013 Jan;7(1):7-15. doi: 10.5009/gnl.2013.7.1.7.

Lim YJ, Phan TM, Dial EJ, Graham DY, Lichtenberger LM. In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012;86(2):171-7. doi: 10.1159/000339882.

Olson A, Diebel LN, Liberati DM. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin. J Trauma Acute Care Surg. 2014 Oct;77(4):570-5; discussion 576. doi: 10.1097/TA.0000000000000378.

Olson A, Diebel LN, Liberati DM. Phosphatidylcholine and the intestinal mucus layer: in vitro efficacy against Clostridium difficile-associated polymorphonuclear neutrophil activation. Am J Surg. 2015 Mar;209(3):493-7. doi: 10.1016/j.amjsurg.2014.10.012.

Piche T. Tight junctions and IBS - the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014 Mar;26(3):296-302. doi: 10.1111/nmo.12315.

Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev. 2017 Sep;279(1):70-89. doi: 10.1111/imr.12567.

Schneider H, Braun A, Füllekrug J, Stremmel W, Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int J Mol Sci. 2010;11(10):4149-64. doi: 10.3390/ijms11104149.

Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol. 2010 May-Jun;44(5):e101-7. doi: 10.1097/MCG.0b013e3181c29860.

Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med. 2007 Nov 6;147(9):603-10. PMID: 17975182.

Stremmel W, Ehehalt R, Staffer S, et al. Mucosal protection by phosphatidylcholine. Dig Dis. 2012;30 Suppl 3:85-91. doi: 10.1159/000342729.

Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005 Jul;54(7):966-71. doi: 10.1136/gut.2004.052316.

Sun J, Shen X, Li Y, et al. Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease. Nutrients. 2016 Jan; 8(1):44. doi: 10.3390/nu8010044.

Treede I, Braun A, Jeliaskova P, et al. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol. 2009 Jul 13;9:53. doi: 10.1186/1471-230X-9-53.

Willumeit R, Schuster A, Iliev P, Linser S, Feyerabend F. Phospholipids as implant coatings. J Mater Sci Mater Med. 2007 Feb;18(2):367-80. doi: 10.1007/s10856-006-0702-9.

Zhao S, Jia L, Gao P, et al. Study on the effect of eicosapentaenoic acid on phospholipids composition in membrane microdomains of tight junctions of epithelial cells by liquid chromatography/electrospray mass spectrometry. J Pharm Biomed Anal. 2008 Jun 9;47(2):343-50. doi: 10.1016/j.jpba.2008.01.005.

Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G722-31. doi: 10.1152/ajpgi.00387.2009.




DOI: https://doi.org/10.22141/2308-2097.51.3.2017.112637

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта